



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

301.VASCULATURE, ENDOTHELIUM, THROMBOSIS AND PLATELETS: BASIC AND TRANSLATIONAL

The Plasma Proteomic Landscape of Thrombotic Events across Multi-Center Cohorts

Iris charlotte Kreft¹, Eva Smit¹, Eleonora Camilleri, MD², Louise Burggraaf³, Nienke Van Rein², Bart Van Vlijmen², Anne-Marije Hulshof⁴, Bas Van Bussel⁵, Frank van Rosmalen⁴, Tom van den Berg⁴, Yvonne Henskens⁶, Hugo Ten Cate, MD⁴, Jonathan Coutinho, MDPH⁷, Marieke Kruip, MD PhD⁸, Jeroen Eikenboom, MDPH⁹, Arie Hoogendijk¹⁰, Suzanne Cannegieter, MDPH¹¹, Maartje Van Den Biggelaar¹⁰

¹ Sanquin Research, Amsterdam, Netherlands

² Leiden University Medical Center, Leiden, NLD

³ Leiden University Medical Center, Leiden, Netherlands

⁴ Maastricht University Medical Center, Maastricht, Netherlands

⁵ Dept. Intensive Care Medicine, Maastricht, NLD

⁶ CARIM - School for cardiovascular disease, Maastricht, Netherlands

⁷ Amsterdam University Medical Centers, Amsterdam, NLD

⁸ Erasmus University Medical Center, Rotterdam, NLD

⁹ Leiden Univ. Medical Center, Leiden, Netherlands

¹⁰ Sanquin Research, Amsterdam, NLD

¹¹ Leiden university medical center, Leiden, NLD

Background: Diagnosis and risk prediction of thrombosis is challenging due to nonspecific symptoms, diverse risk factors, symptom overlap with other conditions and the variability in thrombosis presentations. Little is known on the impact of thrombosis on the plasma proteome across the spectrum of its clinical representations.

Objective: The aim of this study was to explore the plasma proteomic landscape across multi-center thrombosis cohorts. The focus was on identifying protein signatures representative of thrombosis in general or among patients at risk of thrombosis, those with a history of thrombosis, those at acute phase and those with COVID-19 associated thrombosis.

Method: Using state-of-the-art mass spectrometry-based proteomics, we analyzed 420 plasma proteome samples both cross-sectional and longitudinal from 211 patients, including those at risk of thrombosis, in the acute thrombotic phase (cerebral venous sinus thrombosis patients) and with COVID-19-associated thrombosis (**Figure 1**). Linear models and unsupervised co-expression clustering were used to explore common and distinct protein signatures among the cohorts.

Results: Across the analyzed samples 475 proteins were quantified, with 86% showing a CV below 30%, and we found a strong correlation between protein levels quantified by MS and ELISA. Plasma proteomic alterations exhibited variation across cohorts, with the most pronounced changes observed in COVID-19 patients. While co-expression analysis unveiled distinct protein clusters associated with SARS-CoV-2 signaling pathways (CRP, SAA1) and Vitamin K-dependent (VKA) coagulation proteins (F9, F2, F10, PROS, PROC, PROZ, C4BPA), we did not identify a specific protein cluster related to thrombosis (**Figure 2**). Notably, VKA-therapy was associated with decreased abundance of VKA-dependent coagulation proteins, with F10 and PROZ showing significant alterations between patients who experienced a thrombosis compared to healthy controls. We observed an inverse correlation between the International Normalized Ratio and abundance of VKA-dependent coagulation proteins, with an increased correlation of F2 and F9 in patients who experienced a thrombotic event. Additionally, our analysis also highlighted potential variations in multi-center cohorts during sample handling, emphasizing the importance of standardized protocols in ensuring the reliability and comparability of results.

Conclusion: Using a comprehensive MS-based proteomics approach, we identified clear plasma proteomic signatures associated with VKA-treatment and COVID-19, but no distinct thrombosis signature across multi-center thrombosis cohorts.

Disclosures Eikenboom: CSL Behring: Research Funding.




Figure 1: Plasma proteomics workflow: Blood sample collection of patients at risk of thrombosis including those with a history of venous thrombosis embolism (VTE) (MEGA cohort, red) and those who experienced a thrombosis (BLEEDS cohort, orange). Additionally this study includes patients at acute phase, cerebral venous sinus thrombosis (CVST, purple) as well as COVID-19 associated thrombosis from MUMC (lightblue) and BEAT-COVID (blue). To provide a baseline healthy controls (green) were included in this study. The proteomics workflow involves plasma sample preparation followed by LC-MS analysis to generate RAW data files for data analysis.




Figure 2: Protein signatures and dynamics related to disease. A network analysis based on the WGCNA approach reveals the relationships between various protein clusters and their connection to specific biological pathways represented by corresponding WikiPathways. The clusters of proteins are depicted as distinct groups, each highlighting a set of functionally related proteins. The purple lines connecting the clusters indicate a Pearson correlation coefficient ≥ 0.75 . Each cluster is further characterized by shape plots, providing insights into the z-scored intensity of proteins within that cluster. These plots are categorized based on specific cohorts and their thrombosis state.

Figure 1

<https://doi.org/10.1182/blood-2023-185936>